As the SARS-CoV-2 crisis maintains its grip on the world, the pressure to develop and distribute effective treatments and vaccines continues to mount. To spare as many people as possible from this deadly disease, treatments and vaccines that are developed for human use will need to be produced and distributed in massive quantities. So far, there is no approved treatments or vaccines available worldwide. To meet the worldwide demand, drug companies will have to scale up their manufacturing capabilities dramatically.
As numerous therapeutic drug and vaccine candidates make their way through human clinical trials, companies are already planning for how to manufacture any successful molecule on a global scale.
In this planning, the preparation of process liquids and buffers should be considered. These solutions are indispensable for drug development and manufacturing as buffer production remains an important part of the facility footprint, labor requirements, and equipment costs, but can be a logistical challenge. During a crisis, like the current SARS-CoV-2 crisis, buffer outsourcing can be essential to increase manufacturing capacity and speed. Sufficient buffer supplies of appropriate quality will be key to meeting the future large-scale manufacturing needs of any SARS-CoV- 2 therapeutic or vaccine.